Applied Genetic Technologies Corporation has completed enrollment in all dose groups for adult patients with achromatopsia in its phase 1/2 clinical programs, according to a press release.
The company is evaluating the safety and efficacy of rAAV2tYF-PR1.7-hCNGA3 in patients with achromatopsia caused by mutations in the CNGA3 or CNGB3 gene and continues to enroll pediatric patients at higher doses in both trials.
Interim 6-month data reported in January from the dose escalation cohorts of the ongoing clinical trials demonstrated signs of biologic activity as shown by positive changes in light
Uncategorized